George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXeris Biopharma Regulatory News (0A8E)

Share Price Information for Xeris Biopharma (0A8E)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.740313
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.740313
0A8E Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Xeris Pharmaceuticals, Inc 8.3 amend

15 Jun 2021 17:55

RNS Number : 0093C
J.P. Morgan Securities LLC
15 June 2021
 

Ap19

 

 

 

AMENDMENT

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1. KEY INFORMATION

 

Name of person dealing (Note 1)

J.P. Morgan Securities LLC

Company dealt in

Xeris Pharmaceuticals, Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

$0.001 common stock

Date of dealing

09 June 2021

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

4,250,867 6.40

 

764,425 1.15

 

(2) Derivatives (other than options)

590,251 0.89

 

 

(3) Options and agreements to purchase/sell

 

 

Total

4,841,118 7.29

 

764,425 1.15

 

       

 

 

Ap20

 

 

1. DEALINGS (Note 4)

 

(a) Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (USD)

 

(Note 5)

Purchase (New Borrow)

 

Purchase (Loan Return)

 

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

 

Sales

Sales

Sales

Sales

165,300

 

52,400

 

2

 1

 3

 8

 3

 1

 51

 23

 1

 4

 5

 

 51

 1,320

 100

 32

N/A

 

N/A

 

4.1000 USD

4.0900 USD

4.0733 USD

4.0675 USD

4.0633 USD

4.0600 USD

4.0598 USD

4.0583 USD

4.0500 USD

4.0275 USD

4.0240 USD

4.0598 USD

4.0100 USD

4.0025 USD

4.0000 USD

 

 

 

 

 

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(USD) (Note 5)

Equity Swap

Decrease Long

51

4.0598 USD

 

 

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

 

Ap21

 

2. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative

 referred to on this form is referenced. If none, this should be stated.

 

None

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)  NO

 

Date of disclosure

 15 June 2021

Contact name

Alwyn Basch

Telephone number

0207 742 7407

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISESFDFMIEFSEIM
Date   Source Headline
28th Jul 20211:40 pmGNWMan Group PLC : Form 8.3 - Strongbridge biopharma plc
28th Jul 202111:46 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
27th Jul 20213:23 pmRNSXeris Pharmaceuticals, Inc 8.3
27th Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
27th Jul 20212:47 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
27th Jul 202110:46 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
26th Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
26th Jul 20213:01 pmRNSXeris Pharmaceuticals, Inc 8.3
26th Jul 20212:17 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
23rd Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
23rd Jul 20213:18 pmRNSXeris Pharmaceuticals, Inc 8.3
23rd Jul 202111:55 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
23rd Jul 202110:20 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
22nd Jul 20213:20 pmRNSForm 8.3 -Xeris Pharmaceuticals, Inc.
22nd Jul 20213:16 pmRNSXeris Pharmaceuticals, Inc 8.3
22nd Jul 202111:08 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
22nd Jul 202110:50 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
21st Jul 20213:36 pmGNWInvesco ltd: Form 8.3 - Xeris Pharmaceuticals Plc.
21st Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
21st Jul 20213:08 pmRNSXeris Pharmaceuticals, Inc Amnd 8.3
21st Jul 20213:01 pmRNSXeris Pharmaceuticals, Inc 8.3
21st Jul 202111:10 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
21st Jul 202110:36 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
20th Jul 20213:21 pmRNSXeris Pharmaceuticals 8.3
20th Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
20th Jul 202112:49 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
20th Jul 202110:23 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
19th Jul 20213:20 pmRNSForm 8.3 -Xeris Pharmaceuticals, Inc.
19th Jul 20212:33 pmRNSXeris Pharmaceuticals, Inc 8.3
19th Jul 20212:01 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
19th Jul 202110:54 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
16th Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
16th Jul 20213:06 pmRNSXeris Pharmaceuticals, Inc 8.3
16th Jul 202112:45 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
15th Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
15th Jul 20212:51 pmRNSXeris Pharmaceuticals, Inc 8.3
15th Jul 202112:37 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
15th Jul 202112:33 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
14th Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
14th Jul 20212:40 pmRNSXeris Pharmaceuticals, Inc 8.3
14th Jul 202111:40 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
13th Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
13th Jul 20212:20 pmRNSXeris Pharmaceuticals, Inc 8.3
13th Jul 20211:17 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
12th Jul 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
12th Jul 20211:30 pmRNSXeris Pharmaceuticals, Inc 8.3
12th Jul 202110:57 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
12th Jul 202110:01 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
9th Jul 20213:20 pmRNSForm 8.3 -Xeris Pharmaceuticals, Inc.
9th Jul 20212:39 pmRNSXeris Pharmaceuticals, Inc 8.3

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.